Dr. Douglas W. Triffon is a cardiologist in La Jolla, California, who practices at Scripps Clinic. His listed specialties include cardiology, internal medicine, and integrative medicine, and he is part of the Scripps Clinic Division of Integrative Medicine at the Anderson Medical Pavilion (https://www.scripps.org/physicians/5512-douglas-triffon). He has been described as medical director of the Scripps Lipid Clinic (https://www.scripps.org/news_items/7169-new-heart-tests-save-san-diego-man-s-life).
He went to medical school at Ohio State University College of Medicine, finished his internal medicine training at the University of California, San Diego in 1982, and completed a cardiovascular disease fellowship at the University of Colorado Health Sciences Center in 1985 (https://www.scripps.org/physicians/5512-douglas-triffon). He holds California medical license G44525 (https://npiprofile.com/npi/1952358632).
Much of his public work centers on cholesterol and lipid care. He wrote a Scripps teaching presentation called "Advanced Lipid Management" that covers apoB, Lp(a), and the limits of standard risk ratios (https://www.scripps.org/assets/documents/triffon.pdf). In a 2015 local TV segment, Scripps described him as one of the first doctors in San Diego to prescribe a newly approved PCSK9 inhibitor cholesterol drug (https://www.scripps.org/news_items/5381-scripps-cardiologist-weighs-in-on-new-cholesterol-lowering-drug). A Scripps patient story describes a patient who could not tolerate statins being referred to his lipid clinic for diet-based management (https://www.scripps.org/news_items/3181-going-from-good-to-great).
Federal Open Payments records show he received $55,734.08 from drug and device companies across 416 records between 2021 and 2025. The largest payers were Esperion Therapeutics ($32,453.69), Amgen ($7,661.36), Regeneron ($5,011.36), Novartis ($4,010.27), and Amarin Pharma ($3,702.65). These companies make cholesterol and heart medicines. Payments like these are common and legal, and are publicly reported (https://openpaymentsdata.cms.gov/).
Federal law requires drug and device companies to report what they pay clinicians: meals, travel, speaking, consulting, and research. Payments are common and legal; the point is that you can see them.
2021 to 2025
$55,734
416 payments
| 2021 | $34,433 |
| 2022 | $15,904 |
| 2023 | $2,293 |
| 2024 | $1,059 |
| 2025 | $2,045 |
Top payers
- Esperion Therapeutics, Inc.$32,454
- Amgen Inc.$7,661
- Regeneron Healthcare Solutions, Inc.$5,011
- Novartis Pharmaceuticals Corporation$4,010
- Amarin Pharma Inc.$3,703
Payment types
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$41,708
- Food and Beverage$7,526
- Travel and Lodging$3,478
- Consulting Fee$2,532
- Honoraria$475
A word of caution about these numbers
A payment does not mean your doctor is compromised or acting unethically. Most of these entries are drug samples left for patients, or lunch brought in for the office staff, and the amounts are usually small. Research funding and speaking at medical meetings are also normal parts of a clinical career.
As a rough guide, a total under $15,000 a year is usually not a concern. Much larger sums, especially from one company whose product your doctor recommends to you, are worth asking about. You are allowed to ask.
Summary prepared with AI assistance from the public sources linked above. It is not a review, a rating, or an endorsement.